Benzinga

Benzinga

Benzinga

viernes, septiembre 04

Minimed Group Inc

MMEDNASDAQ
Trade with Public
Trade with Public
$23.43
-0.41-1.72%
Últ. Act.: Sep 4, 10:56 AM
Ganancias: Los beneficios de Q1 2027 se publicaron el mar sept 1st, antes de la apertura del mercado
Conferencia telefónica: La conferencia telefónica más reciente comenzó a las 8:45 a. m., hace 3 días
Haz clic para ver el webcast
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoCompararInforme de acciones

Minimed Group Analyst Price Targets

Wall Street analyst price targets and consensus rating for Minimed Group (MMED).

Price Target Range — 3 Quarters

Analyst Consensus — 12 Analysts

11Buy
1Hold
Consensus RatingBuy# Analysts12Avg. Consensus PT$25Upside to Avg. PT+5.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 3, 2026Morgan StanleyKallum TitchmarshPT RaiseOverweight$19→$21
Sep 2, 2026CitigroupJoanne WuenschPT RaiseBuy$23→$26
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Minimed Group, Raises Price Target to $21

Morgan Stanley analyst Kallum Titchmarsh maintains Minimed Group (NASDAQ:MMED) with a Overweight and raises the price target from $19 to $21.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Minimed Group, Raises Price Target to $26

Citigroup analyst Joanne Wuensch maintains Minimed Group (NASDAQ:MMED) with a Buy and raises the price target from $23 to $26.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Minimed Group, Raises Price Target to $27

Evercore ISI Group analyst Daniel Markowitz maintains Minimed Group (NASDAQ:MMED) with a Outperform and raises the price target from $20 to $27.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Minimed Group, Raises Price Target to $26

Wells Fargo analyst Larry Biegelsen maintains Minimed Group (NASDAQ:MMED) with a Overweight and raises the price target from $22 to $26.
Benzinga Newsdesk

These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results

MiniMed Group beat Q1 sales estimates with 16.6% growth to $843M; shares rose 7.1% as analysts raised price targets to $26-$28.
Avi Kapoor

PRO
UBS Maintains Buy on Minimed Group, Raises Price Target to $28

UBS analyst Patrick Wood maintains Minimed Group (NASDAQ:MMED) with a Buy and raises the price target from $25 to $28.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved